Veru (NASDAQ:VERU) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Wednesday, Zacks.com reports.

According to Zacks, “Veru Inc. engages in the development, manufacture and marketing of consumer health care products. It focuses on producing FC2 female condom which provides dual protection against unintended pregnancy and sexually transmitted infections. Veru Inc., formerly known as The Female Health Company, is headquartered in Miami, FL. “

Several other analysts also recently weighed in on the stock. Oppenheimer initiated coverage on shares of Veru in a report on Tuesday, March 19th. They issued an “outperform” rating and a $5.00 target price on the stock. Maxim Group set a $6.00 target price on shares of Veru and gave the company a “buy” rating in a report on Thursday, February 14th. HC Wainwright reaffirmed a “buy” rating and issued a $4.50 target price on shares of Veru in a report on Wednesday, January 23rd. Finally, CIBC initiated coverage on shares of Veru in a report on Wednesday, March 20th. They issued an “outperform” rating and a $5.00 target price on the stock. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $4.40.

Shares of NASDAQ:VERU traded down $0.15 during midday trading on Wednesday, hitting $1.29. The stock had a trading volume of 5,930 shares, compared to its average volume of 144,484. The company has a market cap of $89.08 million, a price-to-earnings ratio of -3.31 and a beta of 0.91. The company has a quick ratio of 1.30, a current ratio of 1.58 and a debt-to-equity ratio of 0.08. Veru has a 1 year low of $1.18 and a 1 year high of $2.37.

Veru (NASDAQ:VERU) last issued its earnings results on Wednesday, February 13th. The company reported ($0.03) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.04) by $0.01. The business had revenue of $6.37 million for the quarter, compared to the consensus estimate of $9.71 million. Veru had a negative net margin of 111.10% and a negative return on equity of 60.83%. On average, research analysts forecast that Veru will post -0.19 EPS for the current year.

In other Veru news, insider Mitchell Shuster Steiner sold 25,600 shares of Veru stock in a transaction dated Wednesday, January 23rd. The shares were sold at an average price of $1.34, for a total transaction of $34,304.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last 90 days, insiders have acquired 38,681 shares of company stock valued at $53,206 and have sold 125,600 shares valued at $184,632. Insiders own 29.50% of the company’s stock.

Several large investors have recently bought and sold shares of the company. Virtu Financial LLC acquired a new position in Veru during the first quarter worth approximately $95,000. Dimensional Fund Advisors LP increased its position in Veru by 328.8% during the third quarter. Dimensional Fund Advisors LP now owns 102,909 shares of the company’s stock worth $146,000 after purchasing an additional 78,909 shares during the last quarter. BlackRock Inc. increased its position in Veru by 9.3% during the fourth quarter. BlackRock Inc. now owns 128,766 shares of the company’s stock worth $180,000 after purchasing an additional 10,956 shares during the last quarter. Geode Capital Management LLC increased its position in Veru by 115.4% during the fourth quarter. Geode Capital Management LLC now owns 215,601 shares of the company’s stock worth $301,000 after purchasing an additional 115,506 shares during the last quarter. Finally, Vanguard Group Inc increased its position in Veru by 1.2% during the third quarter. Vanguard Group Inc now owns 1,199,963 shares of the company’s stock worth $1,704,000 after purchasing an additional 13,650 shares during the last quarter. 8.64% of the stock is owned by institutional investors and hedge funds.

About Veru

Veru Inc operates as an oncology and urology biopharmaceutical company. The company operates through two segments, Commercial, and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation.

See Also: Gap Up Stocks

Get a free copy of the Zacks research report on Veru (VERU)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Veru (NASDAQ:VERU)

Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.